Holen Sie sich die Stockscreener-App
17.43
1.93%
0.33
Handel nachbörslich:
17.69
0.26
+1.49%
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics Inc (CGEM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CGEM|Cullinan Therapeutics Inc|Price:17.775|Chg%:+0.675 - TradingKey
Cullinan Therapeutics Inc (CGEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cullinan Therapeutics Inc (CGEM) Institutional Confidence - TradingKey
TradingKey - TradingKey
ETFs Investing in Cullinan Therapeutics, Inc. Stocks - TradingView
CGEM|Cullinan Therapeutics Inc|Price:17.700|Chg%:+0.600 - TradingKey
Cullinan Therapeutics Inc (CGEM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cullinan Therapeutics Inc (CGEM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cullinan Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGEM - TradingView
Cullinan Therapeutics Inc (CGEM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cullinan Therapeutics (CGEM) Edges Higher as Modest Gains Signal Steady SentimentMACD Signal Stocks - dars.gov.et
Cullinan CSO sells shares, exercises options | CGEM Insider Trading - Stock Titan
Enterprise value to EBIT forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
Price to sales forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
CGEM (NASDAQ) insider resale notice: 8,000 shares proposed, prior 10b5-1 sales noted - Stock Titan
Enterprise value to revenue forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
Price to earnings forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
CGEMCullinan Therapeutics Inc Latest SEC Filings - Finviz
Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase - Stock Titan
Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60 - Stock Titan
EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine - Barchart.com
Cullinan Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGEM) - TradingView
CGEM Forecast — Price Target — Prediction for 2027 - TradingView
Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data – Has The Bull Case Changed? - Sahm
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com - Investing.com Australia
Cullinan Oncology stock hits 52-week high at $17.97 - Investing.com UK
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes - Yahoo Finance
Cullinan Therapeutics Inc (CGEM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cullinan Therapeutics (CGEM) Citi’s 2026 Virtual Oncology Leadership Summit Summary - Quartr
Cullinan Therapeutics (CGEM) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Cullinan Therapeutics (CGEM) Surges 4%: Key Levels to Watch After Recent UptickOpening Range Breakout - dars.gov.et
CULLINAN THERAPEUTICS INC (CGEM) Stock Chart - ChartMill
Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant - Stock Titan
Cullinan Therapeutics (CGEM) grants director 25,319 stock options - Stock Titan
Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM) - Stock Titan
Cullinan Therapeutics (CGEM) director receives stock options for 25,319 shares - Stock Titan
Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options - Stock Titan
Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike - Stock Titan
Cullinan Therapeutics Inc (CGEM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cullinan Therapeutics Inc (CGEM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com
Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay - Stock Titan
Cullinan Therapeutics (CGEM) Edges Lower, Testing Key Support Zone Amid Sector VolatilityEntry Point Alerts - DonanımHaber
Cullinan Therapeutics CSO to join MITCEO Conference panel on advancing patient medicines - Traders Union
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and Viridian Therapeutics (VRDN) - The Globe and Mail
CGEM Reiterated by Wedbush -- Price Target Maintained at $37 - GuruFocus
Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) - Seeking Alpha
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):